Lipocine Inc. (LPCN) stock is falling today: Here’s Why.

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Shares of Lipocine Inc. (LPCN) were declining in intraday trading session despite the release update of LiFT clinical study. LPCN stock price saw a decline of 0.71% to drop at $1.40 a share at the time of this writing. The stock was green in the previous trading session and went high by 0.71% at closing. Let’s dig in to understand the recent events.

LiFT Clinical Study:

An Overview:

LPCN stock today released 36-week positive topline results of its phase 2 proof of concept LiFT study. For individual who do not know LiFT, it is acronym of Liver Fat intervention with oral Testosterone. The study investigated LPCN 1144 in men with suffering from NASH. NASH is the major cause of liver failure and liver transplantation across the globe and unfortunately, there is no approved treatment of it.

Male subjects with confirmed hypogonadal or eugonadal NASH having F1-F3 fibrosis stage and NAFLD Activity Score ≥ 4 participated in the study.  The treatment period was 36 weeks and study team, divided the subjects in three arms with varying daily dose. The primary end point was change in hepatic fat fraction through MRI-PDFF after 12-week treatment. The secondary end point was to analyze the histological change for NASH resolution along with fibrosis improvement.

Results:

Liver fat reduced significantly after 12 weeks treatment with LPCN 1144. The study team observed liver fat reduction relatively by 46.8% and mean absolute reduction was 9.2%. The study team performed Liver biopsies of patients after 36 weeks of study. Treatments with LPCN 1144 showed statistical significant results and met regulatory approval of endpoint of NASH resolution. Overall safety profile showed well tolerance of LPCN 1144 as compared to placebo.

Financial View of LPCN stock:

LPCN stock on August 05, 2021, did announce second quarter 2021 financial results the highlights of which are given below.

  • Lipocine stock suffered a net loss of $6.8 million, or ($0.08) per diluted share in the second quarter of 2021.
  • LPCN spent $1.5 million in research and development expenses , lower than $2.3 million in Q2,2020.
  • General and administrative expenses for the LPCN stock lowered to $1.5 million in Q2,2021 from $2.0 million in Q2,2020.

Balance Sheet of LPCN stock:

By the end of second quarter, LPCN stock had $46.6 million in unrestricted cash, cash equivalents, and marketable investments.

Wrap Up:

Positive topline efficacy results of LiFT study is the positive sign for the LPCN for the future growth. Management is optimistic that LPCN 1144 will prove to be the best option for treating NASH.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts